Article Impact Level: HIGH Data Quality: STRONG Summary of New England Journal of Medicine https://doi.org/10.1056/NEJMoa2510703 Dr. Lana A. Castellucci et al.
Points
- Researchers conducted the international COBRRA trial involving two thousand seven hundred sixty participants to compare the bleeding risks of apixaban and rivaroxaban in patients with acute venous thromboembolism.
- The study found that seven point one percent of patients taking rivaroxaban experienced clinically relevant bleeding compared to only three point three percent of those who were prescribed apixaban.
- Statistical analysis confirmed that while apixaban significantly reduced the hazard of bleeding complications it remained just as effective as rivaroxaban at preventing the recurrence of dangerous blood clots.
- This academically led trial utilized a real world standard of care design across thirty-two sites in three countries to ensure the findings are broadly applicable to diverse patient populations.
- These results provide physicians with highly anticipated evidence to support apixaban as the safer anticoagulant choice for the three-month treatment period following a venous thrombosis diagnosis.
Summary
This research evaluated the comparative safety and efficacy of apixaban and rivaroxaban in the treatment of acute venous thromboembolism (VTE). While both direct oral anticoagulants (DOACs) are standard-of-care options for preventing recurrent thrombosis, clinicians have lacked high-level, head-to-head evidence regarding their relative bleeding risks. The COBRRA trial, an international, academically-led study, enrolled 2,760 participants across 32 sites in Canada, Australia, and Ireland to determine which agent offers a superior safety profile during the critical three-month post-diagnosis period.
The findings demonstrated a significant difference in the primary safety endpoint of clinically relevant bleeding. Participants receiving rivaroxaban experienced a 7.1% bleeding rate at three months, whereas those administered apixaban showed a rate of only 3.3%. This represents more than double the risk of bleeding complications associated with rivaroxaban compared to apixaban. Importantly, the analysis revealed no significant difference between the two cohorts in the risk of recurrent VTE, suggesting that the lower bleeding risk with apixaban does not compromise its antithrombotic efficacy.
The data suggest that apixaban is the safer therapeutic option for patients requiring anticoagulation for acute venous thrombosis. Given that VTE is the third leading cause of cardiovascular death and the most common preventable cause of hospital mortality, these results provide evidence-based clarity for routine clinical practice. By reducing the incidence of major and clinically relevant non-major bleeding without increasing the hazard for clot recurrence, apixaban offers a more favorable benefit-to-risk ratio. These findings are broadly applicable across diverse health systems and emphasize the importance of DOAC selection in long-term venous thrombosis management.
Link to the article: https://www.nejm.org/doi/10.1056/NEJMoa2510703
References
Castellucci, L. A., Chen, V. M., Kovacs, M. J., Lazo-Langner, A., Greenstreet, P., Kahn, S., Côté, B., Schulman, S., De Wit, K., Douketis, J., Suryanarayan, D., Wan, T., Yeo, E., Le Templier, G., Tran, H. A., Willcox, A., Crowther, H. J., Prasad, R., Shivakumar, S., … Rodger, M. (2026). Bleeding risk with apixaban vs. Rivaroxaban in acute venous thromboembolism. New England Journal of Medicine, 394(11), 1051–1060. https://doi.org/10.1056/NEJMoa2510703
